CVRXHealthcare · Medical DevicesThe 7 Wall Street analysts covering CVRx, Inc. hold a median 12-month price target of $12 — +118.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores CVRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own CVRx, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CVRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +118.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | $10 |
| 13 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Aug 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 May 2025 | JP Morgan | Downgrade | Underweight | — |
| 9 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 8 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 8 Apr 2025 | Lake Street | Maintains | Buy | — |
| 5 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | William Blair | Upgrade | Outperform | — |
| 9 Dec 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 30 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
| 30 Oct 2024 | Lake Street | Maintains | Buy | — |
| 30 Oct 2024 | Piper Sandler | Reiterates | Overweight | — |
| 23 Oct 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 10 Sept 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 47% of US stocks
Cheaper than 21% of US stocks
Cheaper than 74% of US stocks
Higher than 71% of US stocks
Higher than 61% of US stocks
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 6% of US stocks
Higher than 12% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVRX appears on the weeks it earns a place.
CVRx announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026 at 1:00 p.m. ET.
Why it matters — The presentation gives CVRx an opportunity to update the investment community on its neuromodulation business at a major industry conference.
The 7 Wall Street analysts covering CVRx, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering CVRx, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CVRx, Inc. 54 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, CVRx, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +118.2% from the last close, and Ticker Nerd's factor model ranks CVRx, Inc. 54 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CVRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $14 over the next 12 months.
CVRx, Inc. returned -27.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
CVRx, Inc. is a pioneering medical device company that focuses on developing innovative therapies to address a variety of cardiovascular conditions.
The most recent item we track (GlobeNewsWire, 28 July 2026): "CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference". CVRx announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026 at 1:00 p.m. ET.
CVRx, Inc. is a pioneering medical device company that focuses on developing innovative therapies to address a variety of cardiovascular conditions. The company's primary product is the Barostim Neo, a neuromodulation device designed to improve heart function by stimulating the body’s baroreceptors, which are essential for regulating blood pressure. CVRx aims to enhance the quality of life for patients with chronic heart failure and other cardiovascular diseases by offering this alternative treatment to traditional drug therapies. With a growing presence in the medical technology industry, CVRx, Inc. collaborates with healthcare providers and institutions worldwide to expand its reach and impact. Founded with a commitment to advancing patient care, the company plays a significant role in the cardiovascular segment, contributing to ongoing improvements in non-invasive treatment options. Headquartered in Minneapolis, Minnesota, CVRx continues to focus on research and development to further refine its technology and expand its product applications in the field of heart health management.
CEO Mr. Kevin Hykes · 223 employees · United States · https://www.barostim.com